Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis

被引:8
|
作者
Ohashi, Kadoaki [1 ]
Ninomiya, Kiichiro [1 ]
Yoshioka, Hiroshige [2 ,20 ]
Bessho, Akihiro [3 ]
Shibayama, Takuo [4 ]
Aoe, Keisuke [5 ]
Ishikawa, Nobuhisa [6 ]
Kozuki, Toshiyuki [7 ]
Kawai, Haruyuki [8 ]
Kuyama, Shoichi [9 ]
Miyoshi, Seigo [10 ]
Fujitaka, Kazunori [11 ]
Obata, Hideto [12 ]
Tsubata, Yukari [13 ]
Awaya, Yoshikazu [14 ]
Inoue, Masaaki [15 ]
Inoue, Koji [16 ]
Horita, Naokatsu [17 ]
Yanai, Hiroyuki [18 ]
Hotta, Katsuyuki [19 ]
Kiura, Katsuyuki [1 ]
机构
[1] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan
[2] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan
[3] Japanese Red Cross Okayama Hosp, Dept Resp Med, Okayama, Japan
[4] Natl Hosp Org, Dept Resp Med, Okayama Med Ctr, Okayama, Japan
[5] Natl Hosp Org, Dept Med Oncol, Yamaguchi Ube Med Ctr, Ube, Yamaguchi, Japan
[6] Hiroshima Prefectural Hosp, Dept Resp Med, Hiroshima, Japan
[7] Natl Hosp Org, Shikoku Canc Ctr, Dept Thorac Oncol & Med, Shikoku, Ehime, Japan
[8] Okayama Saiseikai Gen Hosp, Dept Internal Med, Okayama, Japan
[9] Iwakuni Med Ctr, Dept Resp Med, Iwakuni, Japan
[10] Ehime Univ, Grad Sch Med, Dept Cardiol Pulmonol Hypertens & Nephrol, Matsuyama, Ehime, Japan
[11] Hiroshima Univ Hosp, Dept Resp Med, Hiroshima, Japan
[12] Yamaguchi Ken Saiseikai Shimonoseki Gen Hosp, Dept Resp Med, Shimonoseki, Yamaguchi, Japan
[13] Shimane Univ, Fac Med, Div Med Oncol & Resp Med, Dept Internal Med, Matsue, Shimane, Japan
[14] Miyoshi Cent Hosp, Dept Resp Med, Saitama, Japan
[15] Shimonoseki City Hosp, Dept Chest Surg, Shimonoseki, Yamaguchi, Japan
[16] Ehime Prefectural Cent Hosp, Dept Resp Med, Matsuyama, Ehime, Japan
[17] Kure Kyosai Hosp, Dept Resp Med, Kure, Hiroshima, Japan
[18] Okayama Univ Hosp, Dept Pathol, Okayama, Japan
[19] Okayama Univ Hosp, Ctr Innovat Clin Med, 2-5-1 Shikata Cho Kita Ward, Okayama 7008558, Japan
[20] Kansai Med Univ Hosp, Dept Thorac Oncol, Hirakata, Osaka, Japan
关键词
Epidermal growth factor receptor mutations; Performance status; Human epidermal growth factor receptor-2; Time-To-Treatment failure; GROWTH-FACTOR RECEPTOR; ACQUIRED-RESISTANCE; TRASTUZUMAB EMTANSINE; GENE-MUTATIONS; PHASE-II; CANCER; MUTANT; AMPLIFICATION; OVEREXPRESSION; ADENOCARCINOMA;
D O I
10.1016/j.lungcan.2020.09.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are standard treatment for EGFR-mutated non-small-cell lung carcinoma (NSCLC); however, a biomarker to predict their efficacy has not been established. Although human epidermal growth factor receptor-2 (HER2) aberrations constitute a potential mechanism for acquired resistance to EGFR-TKIs, the impact of HER2 on EGFR-TKI treatment outcomes has not been systematically evaluated. In this post-hoc subgroup study, we examined the impact of HER2 on the effect of EGFR-TKIs in patients with NSCLC harboring EGFR mutations. Materials and Methods: Of 1126 patients with NSCLC enrolled into a prospective cohort study (HER2-CS study), we analyzed data of 356 (32 %) patients with EGFR-mutant tumors. HER2 protein expression levels were determined by immunohistochemistry (IHC) with the gastric cancer criteria. Patients were divided either to an HER2-P group (HER2-IHC2+/3+) or an HER2-N group (HER2-IHC0/1+). We primarily assessed differences in the time-to-treatment failure (TTF) of EGFR-TKI between the groups. Results: The HER2 scoring was as follows: IHC0 (n = 76, 21 %), IHC1+ (n = 199, 56 %), IHC2+ (n = 72, 20 %), and IHC3+ (n = 9, 3 %). The patients' demographics were similar in the HER2-P and HER2-N groups. The HER2-P group showed a significantly shorter EGFR-TKI TTF than the HER2-N group (hazard ratio [HR]: 1.657, 95 % confidence interval [CI]: 1.076-2.552; median: 13.3 vs. 19.1 months). The magnitude of the negative impact of TTF was especially dependent on performance status (PS). HER2 expression significantly deteriorated the TTF in the subgroup with PS 2 (HR: 5.497, 95 % CI: 1.510-20.02), but not in that with better PS (HR: 1.437, 95 % CI: 0.899-2.298) (pinteraction = 0.015). Conclusion: In the current cohort, HER2 protein expression in EGFR-mutant NSCLC may have a negative impact on the effect of EGFR-TKIs, the effect of which was PS dependent.
引用
收藏
页码:83 / 89
页数:7
相关论文
共 50 条
  • [21] Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients
    Trevor J Pugh
    Gwyn Bebb
    Lorena Barclay
    Margaret Sutcliffe
    John Fee
    Chris Salski
    Robert O'Connor
    Cheryl Ho
    Nevin Murray
    Barbara Melosky
    John English
    Jeurgen Vielkind
    Doug Horsman
    Janessa J Laskin
    Marco A Marra
    BMC Cancer, 7
  • [22] The immunoexpression of EGFR, HER2 and HER3 in malignant serous ovarian tumors
    Cirstea, Andreea-Elena
    Stepan, Alex Emilian
    Margaritescu, Claudiu
    Zavoi, Roxana Eugenia
    Olimid, Daniel Alin
    Simionescu, Cristiana Eugenia
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2017, 58 (04): : 1269 - 1273
  • [23] Impact of menopausal status and HER-2/neu protein on efficacy of EGFR-TKI in EGFR mutant patients with non-small cell lung cancer
    Yin, Zi-Jun
    Tu, Hai-Yan
    Fu, Ming
    Zhong, Wen-Zhao
    An, She-Juan
    Yang, Hong-Hong
    Chen, Hua-Jun
    Lin, Hui-Ran
    Wu, Yi-Long
    JOURNAL OF CANCER, 2018, 9 (17): : 2987 - 2993
  • [24] Detection of EGFR and HER2 activating mutations in lung adenocarcinoma by High Resolution Melting Amplicon Analysis
    Willmore-Payne, C
    Holden, JA
    Layfield, LJ
    MODERN PATHOLOGY, 2006, 19 : 319A - 319A
  • [25] Detection of EGFR and HER2 activating mutations in lung adenocarcinoma by high resolution melting amplicon analysis
    Willmore-Payne, C
    Holden, JA
    Layfield, LJ
    LABORATORY INVESTIGATION, 2006, 86 : 319A - 319A
  • [26] Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
    Jiang-Yong Yu
    Si-Fan Yu
    Shu-Hang Wang
    Hua Bai
    Jun Zhao
    Tong-Tong An
    Jian-Chun Duan
    Jie Wang
    ChineseJournalofCancer, 2016, 35 (04) : 171 - 180
  • [27] Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
    Yu, Jiang-Yong
    Yu, Si-Fan
    Wang, Shu-Hang
    Bai, Hua
    Zhao, Jun
    An, Tong-Tong
    Duan, Jian-Chun
    Wang, Jie
    CHINESE JOURNAL OF CANCER, 2016, 35
  • [28] Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance
    Sellappan, Shankar
    Blackler, Adele
    Liao, Wei-Li
    O'Day, Emily
    Xu, Peng
    Thyparambil, Sheeno
    Cecchi, Fabiola
    Hembrough, Todd
    Catenacci, Daniel V. T.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (05): : 503 - 507
  • [29] Targeting HER2-and MET co-amplification in patients with EGFR mutation resistant to EGFR-TKI therapy
    Brandes, V
    Scheffler, M.
    Kambartel, K.
    Ortiz-Cuaran, S.
    Scheel, A.
    Michels, S.
    Nogova, L.
    Fischer, R.
    Abdulla, D.
    Merkelbach-Bruse, S.
    Buettner, R.
    Sos, M. L.
    Wolf, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 172 - 172
  • [30] EGFR and HER2 expression in advanced biliary tract cancer
    Jan Harder
    Oliver Waiz
    Florian Otto
    Michael Geissler
    Manfred Olschewski
    Brigitte Weinhold
    Hubert E Blum
    Annette Schmitt-Graeff
    Oliver G Opitz
    World Journal of Gastroenterology, 2009, 15 (36) : 4511 - 4517